Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

Yasuyoshi Sato,1 Naoki Fukuda,1 Xiaofei Wang,1 Tetsuya Urasaki,1 Akihiro Ohmoto,1 Kenji Nakano,1 Mayu Yunokawa,1 Makiko Ono,1 Yukiko Sato,2 Hiroki Mitani,3 Junichi Tomomatsu,1 Shunji Takahashi1 1Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tok...

全面介紹

書目詳細資料

發表在:	Cancer Management and Research
Main Authors:	Sato Y, Fukuda N, Wang X, Urasaki T, Ohmoto A, Nakano K, Yunokawa M, Ono M, Mitani H, Tomomatsu J, Takahashi S
格式:	Article
語言:	英语
出版:	Dove Medical Press 2020-06-01
主題:	head and neck cancer nivolumab pd-1 immunotherapy immune checkpoint inhibitor checkmate-141
在線閱讀:	https://www.dovepress.com/efficacy-of-nivolumab-for-head-and-neck-cancer-patients-with-primary-s-peer-reviewed-article-CMAR